Cost-effectiveness of single-dose AmBisome pre-emptive treatment for the prevention of cryptococcal meningitis in African low and middle-income countries
© The Author(s) 2022. Published by Oxford University Press on behalf of The International Society for Human and Animal Mycology..
Cryptococcal antigen (CrAg) screening is recommended for patients with advanced HIV to reduce AIDS-related mortality. For asymptomatic CrAg-positive persons, fluconazole pre-emptive therapy is standard, despite a ∼25% failure rate. Single-dose liposomal amphotericin B (AmBisome) is non-inferior to standard treatment for cryptococcal meningitis. We evaluate the threshold of efficacy necessary for AmBisome + fluconazole to be cost-effective as pre-emptive therapy for CrAg-positive persons.We created a decision analytic model to evaluate CrAg screening and treatment in HIV-infected persons with CD4 < 100 cells/μL. Costs were estimated for screening, pre-emptive therapy, and hospitalization for an example low-income country (Uganda) and middle-income country (South Africa). We used a discounted price range of AmBisome® at ${\$}$16.25 to ${\$}$40 per 50 mg vial for both Uganda and South Africa. We estimated AmBisome efficacy from 75 to 95%. Parameter assumptions were based on prospective CrAg screening studies and clinical trials in Africa. Disability adjusted life years (DALYs) were calculated using the age-specific life expectancy in Uganda, per WHO Global Health Observatory data. We modeled the theoretical efficacy of adjunctive AmBisome to determine cost per DALY averted.In South Africa, at ${\$}$16.25 per vial cost and a minimum efficacy of 85%, adjunctive AmBisome is cost-saving compared to fluconazole monotherapy. Compared to fluconazole pre-emptive therapy in Uganda, AmBisome + fluconazole would cost ${\$}$475, ${\$}$220, or ${\$}$136 per DALY averted if meningitis-free survival efficacy was 80, 85, or 90% at ${\$}$24 per vial cost.Investing in AmBisome may be cost-effective in low-income settings compared to using fluconazole pre-emptive therapy alone, if efficacy is 85% or greater. AmBisome pre-emptive therapy appears more cost-efficient in middle-income settings where hospitalization costs for meningitis, and GDP per capita are higher.
LAY SUMMARY: We evaluate the efficacy necessary for AmBisome + fluconazole to be cost-effective to prevent cryptococcal meningitis. We found that if AmBisome pre-emptive therapy has an efficacy of 85% or greater, it is likely to be cost-effective in low-income settings.
Medienart: |
E-Artikel |
---|
Erscheinungsjahr: |
2022 |
---|---|
Erschienen: |
2022 |
Enthalten in: |
Zur Gesamtaufnahme - volume:60 |
---|---|
Enthalten in: |
Medical mycology - 60(2022), 2 vom: 01. Feb. |
Sprache: |
Englisch |
---|
Beteiligte Personen: |
Rajasingham, Radha [VerfasserIn] |
---|
Links: |
---|
Themen: |
7XU7A7DROE |
---|
Anmerkungen: |
Date Completed 02.02.2022 Date Revised 17.12.2022 published: Print Citation Status MEDLINE |
---|
doi: |
10.1093/mmy/myab078 |
---|
funding: |
|
---|---|
Förderinstitution / Projekttitel: |
|
PPN (Katalog-ID): |
NLM335608833 |
---|
LEADER | 01000naa a22002652 4500 | ||
---|---|---|---|
001 | NLM335608833 | ||
003 | DE-627 | ||
005 | 20231225230235.0 | ||
007 | cr uuu---uuuuu | ||
008 | 231225s2022 xx |||||o 00| ||eng c | ||
024 | 7 | |a 10.1093/mmy/myab078 |2 doi | |
028 | 5 | 2 | |a pubmed24n1118.xml |
035 | |a (DE-627)NLM335608833 | ||
035 | |a (NLM)35026017 | ||
035 | |a (PII)myab078 | ||
040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
041 | |a eng | ||
100 | 1 | |a Rajasingham, Radha |e verfasserin |4 aut | |
245 | 1 | 0 | |a Cost-effectiveness of single-dose AmBisome pre-emptive treatment for the prevention of cryptococcal meningitis in African low and middle-income countries |
264 | 1 | |c 2022 | |
336 | |a Text |b txt |2 rdacontent | ||
337 | |a ƒaComputermedien |b c |2 rdamedia | ||
338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
500 | |a Date Completed 02.02.2022 | ||
500 | |a Date Revised 17.12.2022 | ||
500 | |a published: Print | ||
500 | |a Citation Status MEDLINE | ||
520 | |a © The Author(s) 2022. Published by Oxford University Press on behalf of The International Society for Human and Animal Mycology. | ||
520 | |a Cryptococcal antigen (CrAg) screening is recommended for patients with advanced HIV to reduce AIDS-related mortality. For asymptomatic CrAg-positive persons, fluconazole pre-emptive therapy is standard, despite a ∼25% failure rate. Single-dose liposomal amphotericin B (AmBisome) is non-inferior to standard treatment for cryptococcal meningitis. We evaluate the threshold of efficacy necessary for AmBisome + fluconazole to be cost-effective as pre-emptive therapy for CrAg-positive persons.We created a decision analytic model to evaluate CrAg screening and treatment in HIV-infected persons with CD4 < 100 cells/μL. Costs were estimated for screening, pre-emptive therapy, and hospitalization for an example low-income country (Uganda) and middle-income country (South Africa). We used a discounted price range of AmBisome® at ${\$}$16.25 to ${\$}$40 per 50 mg vial for both Uganda and South Africa. We estimated AmBisome efficacy from 75 to 95%. Parameter assumptions were based on prospective CrAg screening studies and clinical trials in Africa. Disability adjusted life years (DALYs) were calculated using the age-specific life expectancy in Uganda, per WHO Global Health Observatory data. We modeled the theoretical efficacy of adjunctive AmBisome to determine cost per DALY averted.In South Africa, at ${\$}$16.25 per vial cost and a minimum efficacy of 85%, adjunctive AmBisome is cost-saving compared to fluconazole monotherapy. Compared to fluconazole pre-emptive therapy in Uganda, AmBisome + fluconazole would cost ${\$}$475, ${\$}$220, or ${\$}$136 per DALY averted if meningitis-free survival efficacy was 80, 85, or 90% at ${\$}$24 per vial cost.Investing in AmBisome may be cost-effective in low-income settings compared to using fluconazole pre-emptive therapy alone, if efficacy is 85% or greater. AmBisome pre-emptive therapy appears more cost-efficient in middle-income settings where hospitalization costs for meningitis, and GDP per capita are higher | ||
520 | |a LAY SUMMARY: We evaluate the efficacy necessary for AmBisome + fluconazole to be cost-effective to prevent cryptococcal meningitis. We found that if AmBisome pre-emptive therapy has an efficacy of 85% or greater, it is likely to be cost-effective in low-income settings | ||
650 | 4 | |a Journal Article | |
650 | 7 | |a Antifungal Agents |2 NLM | |
650 | 7 | |a Antigens, Fungal |2 NLM | |
650 | 7 | |a liposomal amphotericin B |2 NLM | |
650 | 7 | |a Amphotericin B |2 NLM | |
650 | 7 | |a 7XU7A7DROE |2 NLM | |
650 | 7 | |a Fluconazole |2 NLM | |
650 | 7 | |a 8VZV102JFY |2 NLM | |
700 | 1 | |a Nalintya, Elizabeth |e verfasserin |4 aut | |
700 | 1 | |a Israelski, Dennis M |e verfasserin |4 aut | |
700 | 1 | |a Meya, David B |e verfasserin |4 aut | |
700 | 1 | |a Larson, Bruce A |e verfasserin |4 aut | |
700 | 1 | |a Boulware, David R |e verfasserin |4 aut | |
773 | 0 | 8 | |i Enthalten in |t Medical mycology |d 1997 |g 60(2022), 2 vom: 01. Feb. |w (DE-627)NLM097151785 |x 1460-2709 |7 nnns |
773 | 1 | 8 | |g volume:60 |g year:2022 |g number:2 |g day:01 |g month:02 |
856 | 4 | 0 | |u http://dx.doi.org/10.1093/mmy/myab078 |3 Volltext |
912 | |a GBV_USEFLAG_A | ||
912 | |a GBV_NLM | ||
951 | |a AR | ||
952 | |d 60 |j 2022 |e 2 |b 01 |c 02 |